First-of-its-kind flu vaccine could be coming as FDA panel weighs historic shot

Moderna is seeking Food and Drug Administration approval for mFlusiva, a first-of-its-kind flu vaccine designed for people aged 50 and older. An FDA advisory committee is currently meeting to evaluate the shot, which utilizes the same mRNA technology that was instrumental in ending the COVID-19 pandemic. This panel meeting represents a critical step toward a final regulatory decision, aiming to make the vaccine available before the upcoming winter flu season begins in the United States.